BioTelemetry's (BEAT) Holter Analysis Software Receives CE Mark
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
BioTelemetry, Inc. (Nasdaq: BEAT) announced that the Company has received CE mark approval of its Holter analysis software. The software can be used either on a stand-alone basis or in combination with the Company’s family of digital Holter recorders.
Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “With the achievement of this important milestone, we are excited to be one of the only international providers with a complete monitoring solution, offering both devices and software. We believe that the global market offers the Company compelling growth possibilities, and we continue to invest in the expansion of our international operations. While the software currently operates with our legacy Holter recorders, we expect to launch an integrated solution with our newly acquired ePatch device in the near future.”
The Company expects to market the Holter analysis software under the Millennia brand name.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ServiceNow (NOW) Acquires DxContinuum
- General Motors (GM) confirms $1M SEC Ignition Switch Settlement
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!